breast cancer

AZ
Favicon Fierce Biotech

FDA delays ruling on AstraZeneca drug after negative adcomm vote

The FDA deferred its ruling on AstraZeneca’s camizestrant to review analyses filed after an advisory committee voted against the breast cancer asset.
Nick Paul Taylor May 27, 2026 4:43am
race car photo finish speed fast

AZ, Daiichi's Datroway approved in first-line TNBC

May 22, 2026 11:32am
Enhertu

Enhertu secures dual FDA approvals in early breast cancer

May 18, 2026 10:52am
pay deal hand over cash licensing transaction money

Rigel snags Veppanu license from Pfizer, Arvinas for $85M

May 12, 2026 11:35am
A photo finish at a horse race with both horses crossing the finish line

Pfizer, Arvinas' breast cancer med wins FDA approval

May 1, 2026 3:50pm
FDA
Favicon Fierce Biotech

FDA flags concerns for AZ's camizestrant, Truqap ahead of adcomm

Apr 28, 2026 2:47pm